Compare Stocks: PHVS, CYTK, IONS, and ALKS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$43.50 +0.0%	$44.65	$27.00 ▼ $55.67	$7.30B	0.32	2.36 million shs	1.81 million shs
CYTK Cytokinetics	$62.65 -0.3%	$69.38	$54.30 ▼ $88.31	$7.86B	0.41	2.11 million shs	2,320 shs
IONS Ionis Pharmaceuticals	$44.60 +0.7%	$51.06	$42.08 ▼ $86.74	$7.49B	0.38	2.64 million shs	13,740 shs
PHVS Pharvaris	$30.95 +0.9%	$34.12	$21.02 ▼ $43.25	$2.01B	-2.46	441,724 shs	10,566 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-1.43%	+11.26%	-1.58%	-17.92%	+38.25%
CYTK Cytokinetics	-1.70%	-0.90%	-7.00%	-23.27%	+8.79%
IONS Ionis Pharmaceuticals	-2.49%	+3.68%	-1.40%	-20.76%	-38.20%
PHVS Pharvaris	-0.78%	+2.13%	-14.88%	-7.82%	+27.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$43.50 +0.0%	$44.65	$27.00 ▼ $55.67	$7.30B	0.32	2.36 million shs	1.81 million shs
CYTK Cytokinetics	$62.65 -0.3%	$69.38	$54.30 ▼ $88.31	$7.86B	0.41	2.11 million shs	2,320 shs
IONS Ionis Pharmaceuticals	$44.60 +0.7%	$51.06	$42.08 ▼ $86.74	$7.49B	0.38	2.64 million shs	13,740 shs
PHVS Pharvaris	$30.95 +0.9%	$34.12	$21.02 ▼ $43.25	$2.01B	-2.46	441,724 shs	10,566 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-1.43%	+11.26%	-1.58%	-17.92%	+38.25%
CYTK Cytokinetics	-1.70%	-0.90%	-7.00%	-23.27%	+8.79%
IONS Ionis Pharmaceuticals	-2.49%	+3.68%	-1.40%	-20.76%	-38.20%
PHVS Pharvaris	-0.78%	+2.13%	-14.88%	-7.82%	+27.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.68	Moderate Buy	$54.47	25.28% Upside
CYTK Cytokinetics	2.86	Moderate Buy	$105.44	67.74% Upside
IONS Ionis Pharmaceuticals	2.78	Moderate Buy	$89.48	102.11% Upside
PHVS Pharvaris	2.80	Moderate Buy	$58.60	91.13% Upside

Current Analyst Ratings Breakdown

Latest PHVS, CYTK, IONS, and ALKS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/22/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Market Perform ➝ Outperform	$54.00 ➝ $66.00
10/21/2026	IONS Ionis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/20/2026	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$79.00
10/19/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$140.00
10/16/2026	CYTK Cytokinetics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/16/2026	ALKS Alkermes	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$55.00
10/15/2026	CYTK Cytokinetics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	IONS Ionis Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	PHVS Pharvaris	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	IONS Ionis Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral ➝ Buy	$46.00 ➝ $88.00
10/14/2026	CYTK Cytokinetics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$104.00

(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.67B	4.37	$1.65 per share	26.34	$11.02 per share	3.95
CYTK Cytokinetics	$88.04M	88.84	N/A	N/A	($5.39) per share	-11.66
IONS Ionis Pharmaceuticals	$874.09M	8.42	N/A	N/A	$3.02 per share	14.66
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	114.42	140.26	N/A	3.96%	4.15%	2.19%	10/27/2026 (Estimated)
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)

Latest PHVS, CYTK, IONS, and ALKS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	PHVS Pharvaris	-$0.8187	N/A	N/A	N/A	$2.35 million	N/A
11/4/2026	Q3 2026	CYTK Cytokinetics	-$1.44	N/A	N/A	N/A	$41.20 million	N/A
11/4/2026	Q3 2026	IONS Ionis Pharmaceuticals	-$1.22	N/A	N/A	N/A	$181.91 million	N/A
10/27/2026	Q3 2026	ALKS Alkermes	-$0.0809	N/A	N/A	N/A	$463.61 million	N/A
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
CYTK Cytokinetics	N/A	6.66	6.66
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
PHVS Pharvaris	N/A	11.94	11.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
CYTK Cytokinetics	N/A
IONS Ionis Pharmaceuticals	93.86%
PHVS Pharvaris	N/A

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
CYTK Cytokinetics	2.60%
IONS Ionis Pharmaceuticals	1.81%
PHVS Pharvaris	11.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
CYTK Cytokinetics	673	124.43 million	121.20 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
PHVS Pharvaris	148	65.41 million	57.66 million	Optionable

PHVS, CYTK, IONS, and ALKS Headlines

Recent News About These Companies

Pharvaris (NASDAQ:PHVS) Shares Climb 7.4% - Time to Buy?

October 19 at 2:39 PM | marketbeat.com

Pharvaris' Rare Disease Drug Meets Primary, Secondary Goals in Phase 3 Trial

October 9, 2026 | finance.yahoo.com

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

October 9, 2026 | markets.businessinsider.com

Pharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027

October 9, 2026 | rttnews.com

Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

October 8, 2026 | globenewswire.com

Could Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy?

October 8, 2026 | finance.yahoo.com

Pharvaris Stock Gets Higher EPS Forecast from HC Wainwright

October 8, 2026 | marketbeat.com

Pharvaris Stock Earnings Estimates Reduced by HC Wainwright

October 7, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (AGMB) and Pharvaris (PHVS)

October 7, 2026 | theglobeandmail.com

Pharvaris Study Shows HAE Patients Prefer Oral Prophylaxis Over Injections

October 5, 2026 | rttnews.com

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

October 5, 2026 | globenewswire.com

Pharvaris N.V. (NASDAQ:PHVS) Stock Has Consensus Price Target of $59.87

September 29, 2026 | marketbeat.com

Bank of America Corp DE Makes New Investment in Pharvaris N.V. $PHVS

September 29, 2026 | marketbeat.com

Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $395,575.45 in Stock

September 25, 2026 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Director Sells $28,952.00 in Stock

September 25, 2026 | insidertrades.com

Johannes Gerardus Chri Schikan Sells 800 Shares of Pharvaris (NASDAQ:PHVS) Stock

September 24, 2026 | marketbeat.com

Pharvaris (NASDAQ:PHVS) CFO David Nassif Sells 6,000 Shares of Stock

September 24, 2026 | insidertrades.com

Pharvaris (NASDAQ:PHVS) CFO Sells $218,820.00 in Stock

September 23, 2026 | marketbeat.com

Robert Glassman Sells 14,493 Shares of Pharvaris (NASDAQ:PHVS) Stock

September 22, 2026 | insidertrades.com

What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?

September 19, 2026 | finance.yahoo.com

Robert Glassman Sells 8,667 Shares of Pharvaris (NASDAQ:PHVS) Stock

September 18, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PHVS, CYTK, IONS, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

$43.50 +0.02 (+0.04%)

As of 09:34 AM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Cytokinetics NASDAQ:CYTK

$62.64 -0.22 (-0.34%)

As of 09:35 AM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Ionis Pharmaceuticals NASDAQ:IONS

$44.60 +0.33 (+0.75%)

As of 09:35 AM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Pharvaris NASDAQ:PHVS

$30.95 +0.29 (+0.93%)

As of 09:35 AM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHVS, CYTK, IONS, and ALKS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHVS, CYTK, IONS, and ALKS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHVS, CYTK, IONS, and ALKS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHVS, CYTK, IONS, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

Cytokinetics NASDAQ:CYTK

Ionis Pharmaceuticals NASDAQ:IONS

Pharvaris NASDAQ:PHVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHVS, CYTK, IONS, and ALKS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHVS, CYTK, IONS, and ALKS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHVS, CYTK, IONS, and ALKS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHVS, CYTK, IONS, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

Cytokinetics NASDAQ:CYTK

Ionis Pharmaceuticals NASDAQ:IONS

Pharvaris NASDAQ:PHVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools